STOCK TITAN

[Form 4] ProMIS Neurosciences Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Jeremy M. Sclar, a director of ProMIS Neurosciences Inc. (PMN), reported multiple transactions in July 2025 that materially changed his beneficial holdings. On July 25, 2025 the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A, 697,674 Tranche B and 697,674 Tranche C purchase warrants, each converting to one common share. Although original exercise prices ranged from $2.02 to $2.50, the exercises were completed at $0.83518 per share following an offer accepted by the issuer. The JS Trust subsequently acquired, on July 29, 2025, a warrant to purchase 3,139,533 common shares exercisable at $1.25 and expiring five years after issuance. The report also shows a disposition of 65,000 common shares held through Crocker Mountain LLC.

Jeremy M. Sclar, amministratore di ProMIS Neurosciences Inc. (PMN), ha comunicato più operazioni in luglio 2025 che hanno modificato in modo sostanziale le sue partecipazioni. Il 25 luglio 2025 il Jeremy M. Sclar 2012 Irrevocable Family Trust (il "JS Trust") ha esercitato 697.674 warrant di Tranche A, 697.674 di Tranche B e 697.674 di Tranche C, ciascuno convertibile in una azione ordinaria. Pur avendo i prezzi di esercizio originali compresi tra 2,02 e 2,50 dollari, gli esercizi sono stati completati a 0,83518 dollari per azione in seguito a un'offerta accettata dall'emittente. Il JS Trust ha poi acquisito, il 29 luglio 2025, un warrant per l'acquisto di 3.139.533 azioni ordinarie esercitabile a 1,25 dollari e con scadenza cinque anni dopo l'emissione. Il rapporto segnala inoltre la cessione di 65.000 azioni ordinarie detenute tramite Crocker Mountain LLC.

Jeremy M. Sclar, director de ProMIS Neurosciences Inc. (PMN), informó varias operaciones en julio de 2025 que cambiaron materialmente sus participaciones. El 25 de julio de 2025, el Jeremy M. Sclar 2012 Irrevocable Family Trust (el "JS Trust") ejerció 697.674 garantías de la Tranche A, 697.674 de la Tranche B y 697.674 de la Tranche C, cada una convertible en una acción ordinaria. Aunque los precios de ejercicio originales oscilaban entre 2,02 y 2,50 dólares, los ejercicios se efectuaron a 0,83518 dólares por acción tras una oferta aceptada por el emisor. Posteriormente, el 29 de julio de 2025, el JS Trust adquirió una garantía para comprar 3.139.533 acciones ordinarias ejercitable a 1,25 dólares y con vencimiento cinco años después de su emisión. El informe también muestra la disposición de 65.000 acciones ordinarias mantenidas a través de Crocker Mountain LLC.

ProMIS Neurosciences Inc.(PMN) 이사인 Jeremy M. Sclar는 2025년 7월에 그의 실질 보유에 중대한 변화를 초래한 여러 건의 거래를 보고했습니다. 2025년 7월 25일 Jeremy M. Sclar 2012 Irrevocable Family Trust(이하 "JS Trust")는 각각 보통주 1주로 전환되는 Tranche A 697,674건, Tranche B 697,674건, Tranche C 697,674건의 워런트를 행사했습니다. 원래 행사가격은 주당 $2.02에서 $2.50 사이였으나, 발행사가 수락한 오퍼에 따라 주당 $0.83518로 행사가 완료되었습니다. JS Trust는 이후 2025년 7월 29일에 주당 $1.25에 행사 가능하고 발행일로부터 5년 만료되는 3,139,533주를 매수할 수 있는 워런트를 취득했습니다. 보고서에는 또한 Crocker Mountain LLC를 통해 보유하던 보통주 65,000주의 처분도 기재되어 있습니다.

Jeremy M. Sclar, administrateur de ProMIS Neurosciences Inc. (PMN), a déclaré plusieurs opérations en juillet 2025 ayant modifié de manière substantielle ses avoirs bénéficiaires. Le 25 juillet 2025, le Jeremy M. Sclar 2012 Irrevocable Family Trust (le « JS Trust ») a exercé 697 674 warrants de la Tranche A, 697 674 de la Tranche B et 697 674 de la Tranche C, chacun convertible en une action ordinaire. Bien que les prix d'exercice initiaux variaient entre 2,02 $ et 2,50 $, les exercices ont été effectués à 0,83518 $ par action suite à une offre acceptée par l'émetteur. Le JS Trust a ensuite acquis, le 29 juillet 2025, un warrant permettant d'acheter 3 139 533 actions ordinaires, exerçable à 1,25 $ et arrivant à échéance cinq ans après son émission. Le rapport indique également la cession de 65 000 actions ordinaires détenues via Crocker Mountain LLC.

Jeremy M. Sclar, Direktor von ProMIS Neurosciences Inc. (PMN), meldete mehrere Transaktionen im Juli 2025, die seine wirtschaftlichen Beteiligungen erheblich verändert haben. Am 25. Juli 2025 übte der Jeremy M. Sclar 2012 Irrevocable Family Trust (der "JS Trust") 697.674 Tranche-A-Warrants, 697.674 Tranche-B-Warrants und 697.674 Tranche-C-Warrants aus, die jeweils in eine Stammaktie umwandelbar sind. Obwohl die ursprünglichen Ausübungspreise zwischen 2,02 und 2,50 USD lagen, wurden die Ausübungen nach einem vom Emittenten akzeptierten Angebot zu je 0,83518 USD pro Aktie durchgeführt. Der JS Trust erwarb anschließend am 29. Juli 2025 einen Warrant zum Kauf von 3.139.533 Stammaktien, ausübbar zu 1,25 USD und mit einer Laufzeit von fünf Jahren ab Ausstellung. Der Bericht weist zudem eine Veräußerung von 65.000 Stammaktien aus, die über Crocker Mountain LLC gehalten wurden.

Positive
  • None.
Negative
  • None.

Insights

TL;DR Director increased indirect ownership by exercising multiple warrant tranches at a reduced price and acquired a large five-year warrant, while disposing of 65,000 shares.

The filing documents concentrated transactions by the JS Trust: three warrant tranches of 697,674 warrants each were exercised into common shares at an agreed reduced price of $0.83518 per share despite higher original exercise prices. The trust also purchased a separate warrant covering 3,139,533 shares at $0.1875 per underlying share price for the warrant, exercisable at $1.25 and expiring in five years. Holdings are reported as indirect through the JS Trust and Crocker Mountain LLC, increasing beneficial ownership counts reported after the transactions. These are material insider actions demonstrating capital deployment into the issuer via warrant exercises and a newly acquired long-dated warrant.

TL;DR Director exercises and warrant purchase change insider stake and require disclosure of related-party control; one small disposition was reported.

The disclosure clarifies that the JS Trust is governed under Massachusetts law with Mr. Sclar's spouse as a trustee and that Crocker Mountain LLC is managed by Mr. Sclar, explaining the indirect ownership reporting. The coordinated exercise of three warrant tranches and the separate acquisition of a large five-year warrant are properly reported under Section 16. The filing also reports a disposition of 65,000 shares held via Crocker Mountain LLC. From a governance standpoint, the report provides transparency on the trust and LLC relationships but does not include additional contractual terms beyond exercise prices and expiration for the new warrant.

Jeremy M. Sclar, amministratore di ProMIS Neurosciences Inc. (PMN), ha comunicato più operazioni in luglio 2025 che hanno modificato in modo sostanziale le sue partecipazioni. Il 25 luglio 2025 il Jeremy M. Sclar 2012 Irrevocable Family Trust (il "JS Trust") ha esercitato 697.674 warrant di Tranche A, 697.674 di Tranche B e 697.674 di Tranche C, ciascuno convertibile in una azione ordinaria. Pur avendo i prezzi di esercizio originali compresi tra 2,02 e 2,50 dollari, gli esercizi sono stati completati a 0,83518 dollari per azione in seguito a un'offerta accettata dall'emittente. Il JS Trust ha poi acquisito, il 29 luglio 2025, un warrant per l'acquisto di 3.139.533 azioni ordinarie esercitabile a 1,25 dollari e con scadenza cinque anni dopo l'emissione. Il rapporto segnala inoltre la cessione di 65.000 azioni ordinarie detenute tramite Crocker Mountain LLC.

Jeremy M. Sclar, director de ProMIS Neurosciences Inc. (PMN), informó varias operaciones en julio de 2025 que cambiaron materialmente sus participaciones. El 25 de julio de 2025, el Jeremy M. Sclar 2012 Irrevocable Family Trust (el "JS Trust") ejerció 697.674 garantías de la Tranche A, 697.674 de la Tranche B y 697.674 de la Tranche C, cada una convertible en una acción ordinaria. Aunque los precios de ejercicio originales oscilaban entre 2,02 y 2,50 dólares, los ejercicios se efectuaron a 0,83518 dólares por acción tras una oferta aceptada por el emisor. Posteriormente, el 29 de julio de 2025, el JS Trust adquirió una garantía para comprar 3.139.533 acciones ordinarias ejercitable a 1,25 dólares y con vencimiento cinco años después de su emisión. El informe también muestra la disposición de 65.000 acciones ordinarias mantenidas a través de Crocker Mountain LLC.

ProMIS Neurosciences Inc.(PMN) 이사인 Jeremy M. Sclar는 2025년 7월에 그의 실질 보유에 중대한 변화를 초래한 여러 건의 거래를 보고했습니다. 2025년 7월 25일 Jeremy M. Sclar 2012 Irrevocable Family Trust(이하 "JS Trust")는 각각 보통주 1주로 전환되는 Tranche A 697,674건, Tranche B 697,674건, Tranche C 697,674건의 워런트를 행사했습니다. 원래 행사가격은 주당 $2.02에서 $2.50 사이였으나, 발행사가 수락한 오퍼에 따라 주당 $0.83518로 행사가 완료되었습니다. JS Trust는 이후 2025년 7월 29일에 주당 $1.25에 행사 가능하고 발행일로부터 5년 만료되는 3,139,533주를 매수할 수 있는 워런트를 취득했습니다. 보고서에는 또한 Crocker Mountain LLC를 통해 보유하던 보통주 65,000주의 처분도 기재되어 있습니다.

Jeremy M. Sclar, administrateur de ProMIS Neurosciences Inc. (PMN), a déclaré plusieurs opérations en juillet 2025 ayant modifié de manière substantielle ses avoirs bénéficiaires. Le 25 juillet 2025, le Jeremy M. Sclar 2012 Irrevocable Family Trust (le « JS Trust ») a exercé 697 674 warrants de la Tranche A, 697 674 de la Tranche B et 697 674 de la Tranche C, chacun convertible en une action ordinaire. Bien que les prix d'exercice initiaux variaient entre 2,02 $ et 2,50 $, les exercices ont été effectués à 0,83518 $ par action suite à une offre acceptée par l'émetteur. Le JS Trust a ensuite acquis, le 29 juillet 2025, un warrant permettant d'acheter 3 139 533 actions ordinaires, exerçable à 1,25 $ et arrivant à échéance cinq ans après son émission. Le rapport indique également la cession de 65 000 actions ordinaires détenues via Crocker Mountain LLC.

Jeremy M. Sclar, Direktor von ProMIS Neurosciences Inc. (PMN), meldete mehrere Transaktionen im Juli 2025, die seine wirtschaftlichen Beteiligungen erheblich verändert haben. Am 25. Juli 2025 übte der Jeremy M. Sclar 2012 Irrevocable Family Trust (der "JS Trust") 697.674 Tranche-A-Warrants, 697.674 Tranche-B-Warrants und 697.674 Tranche-C-Warrants aus, die jeweils in eine Stammaktie umwandelbar sind. Obwohl die ursprünglichen Ausübungspreise zwischen 2,02 und 2,50 USD lagen, wurden die Ausübungen nach einem vom Emittenten akzeptierten Angebot zu je 0,83518 USD pro Aktie durchgeführt. Der JS Trust erwarb anschließend am 29. Juli 2025 einen Warrant zum Kauf von 3.139.533 Stammaktien, ausübbar zu 1,25 USD und mit einer Laufzeit von fünf Jahren ab Ausstellung. Der Bericht weist zudem eine Veräußerung von 65.000 Stammaktien aus, die über Crocker Mountain LLC gehalten wurden.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sclar Jeremy M.

(Last) (First) (Middle)
33 BOYLSTON STREET, SUITE 3000

(Street)
CHESTNUT HILL MA 02467

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares, no par value 07/25/2025 X(1) 697,674 A (1) 2,315,111 I By: Jeremy M. Sclar 2012 Irrevocable Family Trust(2)
Common Shares, no par value 07/25/2025 X(3) 697,674 A (3) 3,012,785 I By JS Trust(2)
Common Shares, no par value 07/25/2025 X(4) 697,674 A (4) 3,710,459 I By JS Trust(2)
Common Shares, no par value 1,155,726 I By Crocker Mountain LLC(5)
Common Shares, no par value 65,000 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Tranche A Common Share Purchase Warrants (1) 07/25/2025 X 697,674 (1) (1) Common Shares 697,674 $0 0 I See footnote(2)
Tranche B Common Share Purchase Warrants (3) 07/25/2025 X 697,674 (3) (3) Common Shares 697,674 $0 0 I See footnote(2)
Tranche C Common Share Purchase Warrants (4) 07/25/2025 X 697,674 (4) (4) Common Shares 697,674 $0 0 I See footnote(2)
Warrant to Purchase Common Shares (6) 07/29/2025 P 3,139,533 (6) (6) Common Shares 3,139,533 (6) 3,139,533 I See footnote(2)
Explanation of Responses:
1. On July 25, 2025, the Jeremy M. Sclar 2012 Irrevocable Family Trust (the "JS Trust") exercised 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.
2. Held through the JS Trust, a trust formed under a trust instrument governed by the laws of the Commonwealth of Massachusetts. Mr Sclar's spouse is one of the trustees of the JS Trust.
3. On July 25, 2025, the JS Trust exercised 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.
4. On July 25, 2025, the JS Trust exercised 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by the JS Trust and an acceptance by the Issuer, were exercised in full at an exercise price of $0.83518 per share.
5. Held through Crocker Mountain LLC, a Maine Limited liability company ("Crocker Mountain"). Mr Sclar is the sole manager of Crocker Mountain.
6. On July 29, 2025, the JS Trust acquired a warrant to purchase 3,139,533 Common Shares at an exercise price of $1.25 per share. The purchase price for the warrant was $0.1875 per Common Share underlying the warrant. The warrant is currently exercisable and expires five years after the date of issuance.
/s/ Jeremy M. Sclar 09/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Jeremy M. Sclar report for PMN?

The filing shows the JS Trust exercised three warrant tranches of 697,674 warrants each into common shares on 07/25/2025 and acquired a warrant for 3,139,533 shares on 07/29/2025; it also shows a disposition of 65,000 shares via Crocker Mountain LLC.

At what price were the Tranche A, B and C warrants exercised?

Although original exercise prices were $2.02 for Tranches A and B and $2.50 for Tranche C, the JS Trust exercised all three tranches at an accepted exercise price of $0.83518 per share.

What are the terms of the large warrant acquired by the JS Trust?

The JS Trust purchased a warrant covering 3,139,533 common shares with an exercise price of $1.25 per share; the purchase price for the warrant was $0.1875 per underlying share and the warrant expires five years after issuance.

How are Mr. Sclar's holdings held or controlled according to the filing?

Holdings are reported indirectly: through the Jeremy M. Sclar 2012 Irrevocable Family Trust (JS Trust) and through Crocker Mountain LLC, of which Mr. Sclar is the sole manager; the JS Trust has Mr. Sclar's spouse as a trustee.

How many shares did the JS Trust beneficially own following the reported transactions?

The filing lists incremental beneficial ownership totals after each exercise: 2,315,111; 3,012,785; and 3,710,459 common shares for the respective entries, reflecting cumulative indirect holdings.
Promis Neuroscie

NASDAQ:PMN

PMN Rankings

PMN Latest News

PMN Latest SEC Filings

PMN Stock Data

20.72M
40.64M
21.56%
25.49%
0.1%
Biotechnology
Pharmaceutical Preparations
Link
Canada
TORONTO